Grace Therapeutics 株価情報 (NASDAQ: GRCE)

最新ニュース Grace Therapeutics (NASDAQ:GRCE) 株価情報

Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Grace Therapeutics Inc

<p>Scotiabank  analyst Greg Harrison   maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $433 to $450.</p>


News

Price Target

Analyst Ratings

VRTX

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $450

<p>Cantor Fitzgerald  analyst Olivia Brayer   reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and maintains $480 price target.</p>


Reiteration

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target

<p>Scotiabank  analyst  Allan Verkhovski   maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Sector Outperform and raises the price target from $300 to $400.</p>


MNDY

Scotiabank Maintains Sector Outperform on Monday.Com, Raises Price Target to $400

<p><a href="https://event.webcasts.com/starthere.jsp?ei=1705636&amp;tp_key=ba14762bab&amp;tp_special=8" title="https://event.webcasts.com/starthere.jsp?ei=1705636&amp;tp_key=ba14762bab&amp;tp_special=8">https://event.webcasts.com/starthere.jsp?ei=1705636&amp;tp_key=ba14762bab&amp;tp_special=8</a></p>


Guidance

JPMorgan CFO Says Board Is Thinking About Succession Planning With Fairness And Focus As Ever

<p>Scotiabank  analyst George Farmer   maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Sector Outperform and raises the price target from $22 to $23.</p>


INMB

Scotiabank Maintains Sector Outperform on INmune Bio, Raises Price Target to $23

WIIM

CARR

Carrier Global shares are trading lower after the company reported worse-than-expected Q4 sales results.

<p><strong>Edgewell Personal Care Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) reported downbeat financial results for the <a href="https://www.benzinga.com/quote/EPC/earnings">first quarter on Monday</a>.</p>
<p>Edgewell Personal Care reported quarterly adjusted earnings of 7 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $478.40 million which missed the analyst consensus estimate of $480.07 million.</p>
<p>Edgewell Personal Care said it sees FY25 adjusted EPS of $3.15 to $3.35, versus estimates of $3.18.</p>
<p>Edgewell Personal Care shares gained 2.5% to trade at $29.33 on Tuesday.</p>
<p>These analysts made changes to their price targets on Edgewell Personal Care following earnings announcement.</p>
<ul>
<li>Morgan Stanley analyst Dara Mohsenian maintained Edgewell Personal Care with an Underweight and lowered the price target from $35 to $32.</li>
<li>Wells Fargo analyst Chris Carey maintained the stock with an Overweight and lowered the price target from $37 to $35.</li>
<li>RBC Capital analyst Nik Modi maintained Edgewell Personal Care with an Outperform and lowered the price target from $48 to $43.</li>
<li>Barclays analyst Lauren Lieberman maintained the stock with an Equal-Weight and lowered the price target from $33 to $30.</li>
</ul>
<p><strong>Considering buying EPC stock? Here&#8217;s what analysts think:</strong> </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="619" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11094659/image-96-1024x619.png" alt="" class="wp-image-776722" style="width:707px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11094659/image-96-1024x619.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11094659/image-96-300x181.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11094659/image-96-768x464.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11094659/image-96.png 1096w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></strong></li>
</ul>


Earnings

Markets

Trading Ideas

Edgewell Personal Care Analysts Cut Their Forecasts After Weak Earnings

<p>Cantor Fitzgerald  analyst Yi Fu Lee   initiates coverage on Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) with a Overweight rating and announces Price Target of $11.</p>


Initiation

DOMO

Cantor Fitzgerald Initiates Coverage On Domo with Overweight Rating, Announces Price Target of $11

Dividends

PSEG Increases Quarterly Dividend From $0.60 To $0.63

<p>Financial giants have made a conspicuous bullish move on PayPal Holdings. Our analysis of options history for PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $131,116, and 5 were calls, valued at $227,058.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $97.5 for PayPal Holdings over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PayPal Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PayPal Holdings's significant trades, within a strike price range of $65.0 to $97.5, over the past month.</p>
<h3>PayPal Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739285151_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$9.1</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$70.00</td>
<td>$63.0K</td>
<td>384</td>
<td align="right">3</td>
</tr>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$23.7</td>
<td>$22.3</td>
<td>$22.31</td>
<td>$97.50</td>
<td>$51.2K</td>
<td>188</td>
<td align="right">24</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.15</td>
<td>$3.0</td>
<td>$3.15</td>
<td>$77.50</td>
<td>$48.1K</td>
<td>1.8K</td>
<td align="right">2</td>
</tr>
<tr>
<td>PYPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$15.65</td>
<td>$15.2</td>
<td>$15.65</td>
<td>$65.00</td>
<td>$46.9K</td>
<td>33</td>
<td align="right">30</td>
</tr>
<tr>
<td>PYPL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.25</td>
<td>$3.2</td>
<td>$3.25</td>
<td>$77.50</td>
<td>$45.5K</td>
<td>5.4K</td>
<td align="right">147</td>
</tr>
</tbody>
</table>
</p>
<h3>About PayPal Holdings</h3>
<p>PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 426 million active accounts at the end of 2023. The company also owns Venmo, a person-to-person payment platform.</p>
<p>After a thorough review of the options trading surrounding PayPal Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is PayPal Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 718,045, the PYPL's price is down by -1.56%, now at $77.02. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PayPal Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

PYPL

PayPal Holdings Unusual Options Activity For February 11

<p>Deep-pocketed investors have adopted a bullish approach towards Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Advanced Micro Devices. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 20% bearish. Among these notable options, 5 are puts, totaling $223,942, and 5 are calls, amounting to $158,797.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $95.0 to $200.0 for Advanced Micro Devices over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Advanced Micro Devices's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Advanced Micro Devices's whale trades within a strike price range from $95.0 to $200.0 in the last 30 days. </p>
<h3>Advanced Micro Devices Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739285146_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$76.8</td>
<td>$73.0</td>
<td>$73.45</td>
<td>$180.00</td>
<td>$88.1K</td>
<td>304</td>
<td align="right">12</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$5.75</td>
<td>$5.65</td>
<td>$5.65</td>
<td>$95.00</td>
<td>$44.0K</td>
<td>3.7K</td>
<td align="right">73</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$31.35</td>
<td>$31.2</td>
<td>$31.35</td>
<td>$110.00</td>
<td>$37.6K</td>
<td>2.3K</td>
<td align="right">3</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$1.75</td>
<td>$1.73</td>
<td>$1.75</td>
<td>$110.00</td>
<td>$35.0K</td>
<td>6.7K</td>
<td align="right">968</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$6.85</td>
<td>$6.8</td>
<td>$6.8</td>
<td>$105.00</td>
<td>$33.9K</td>
<td>4.4K</td>
<td align="right">50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Advanced Micro Devices</h3>
<p>Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.</p>
<h3>Current Position of Advanced Micro Devices</h3>
<ul>
<li>With a trading volume of 929,896, the price of AMD is down by -0.73%, reaching $109.67.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Advanced Micro Devices</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $167.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Advanced Micro Devices, which currently sits at a price target of $250.<br />
&#x2A; An analyst from Benchmark persists with their Buy rating on Advanced Micro Devices, maintaining a target price of $170.<br />
&#x2A; An analyst from B of A Securities persists with their Neutral rating on Advanced Micro Devices, maintaining a target price of $135.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Advanced Micro Devices with a target price of $140.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Advanced Micro Devices, targeting a price of $140. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Advanced Micro Devices options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Smart Money Is Betting Big In AMD Options

<p>Deep-pocketed investors have adopted a bearish approach towards Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in META usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Meta Platforms. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 6 are puts, totaling $605,443, and 5 are calls, amounting to $981,482.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $600.0 to $730.0 for Meta Platforms during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale activity within a strike price range from $600.0 to $730.0 in the last 30 days. </p>
<h3>Meta Platforms Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739285141_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$78.9</td>
<td>$77.05</td>
<td>$78.2</td>
<td>$637.50</td>
<td>$781.4K</td>
<td>222</td>
<td>100</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$39.2</td>
<td>$38.85</td>
<td>$38.85</td>
<td>$725.00</td>
<td>$194.2K</td>
<td>495</td>
<td>99</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.4</td>
<td>$710.00</td>
<td>$162.7K</td>
<td>3.4K</td>
<td>1.7K</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$4.2</td>
<td>$4.05</td>
<td>$4.1</td>
<td>$700.00</td>
<td>$102.5K</td>
<td>6.9K</td>
<td>1.9K</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$45.25</td>
<td>$44.9</td>
<td>$45.0</td>
<td>$730.00</td>
<td>$90.0K</td>
<td>524</td>
<td>28</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<p>Having examined the options trading patterns of Meta Platforms, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Meta Platforms</h3>
<ul>
<li>Currently trading with a volume of 269,975, the META's price is down by -0.73%, now at $712.19. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 71 days.</li>
</ul>
<h3>What Analysts Are Saying About Meta Platforms</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $752.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Market Perform rating on Meta Platforms with a target price of $610.<br />
&#x2A; An analyst from UBS persists with their Buy rating on Meta Platforms, maintaining a target price of $786.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Meta Platforms, maintaining a target price of $770.<br />
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Meta Platforms, maintaining a target price of $846.<br />
&#x2A; An analyst from Baird persists with their Outperform rating on Meta Platforms, maintaining a target price of $750. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Meta Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Meta Platforms

<p>Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) has outperformed the market over the past 20 years by 4.57% on an annualized basis producing an average annual return of 12.98%. Currently, Trane Technologies has a market capitalization of $80.98 billion. </p>
<p><strong>Buying $100 In TT:</strong> If an investor had bought $100 of TT stock 20 years ago, it would be worth <strong>$1,145.06</strong> today based on a price of $359.87 for TT at the time of writing.</p>
<h3>Trane Technologies's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739285122_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Watching Tempus, Company To Report Q4 And FY24 Financial Results On Feb. 24

<p>Barclays  analyst Gena Wang   maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $435 to $467.</p>


Barclays Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $467

GSAT

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

<p><strong>Carrier Global Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) shares are trading lower after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43618132/carrier-reports-strong-2024-results-and-announces-2025-outlook" rel="noreferrer noopener">reported mixed fourth-quarter results</a>.</p>
<p>Net sales rose 19% year over year to $5.148 billion, missing the consensus of $5.275 billion. Net sales included 6% organic growth and 13% net contribution from acquisitions and divestitures.</p>
<p>HVAC sales grew 11% organically, led by strong growth in America. EMEA remained flat organically, while Asia Pacific saw slight gains, driven by Japan and South Asia.</p>
<p>Refrigeration sales declined 6% organically, mainly due to lower North America truck and trailer sales, while other segments remained flat.</p>
<p>GAAP operating profit of $774 million was up over 44% from last year, boosted by a Commercial Refrigeration sale. Adjusted operating&nbsp;profit grew 65% to $678 million, driven by Viessmann, organic growth, and productivity gains.</p>
<p>The operating margin expanded by 255 bps to 15%, and the adjusted operating margin expanded by 370 bps to 13.2%.</p>
<p>The company reported adjusted EPS of $0.54 (+50% YoY), <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">beating the consensus of $0.50.</a></p>
<p>Operating cash flow for fiscal 2024 totaled $563 million, and capital expenditures were $519 million, resulting in a free cash flow of $30 million.</p>
<p>The company exited the quarter with cash and cash equivalents worth $3.969 billion and net debt of $8.309 billion.</p>
<p>&#8220;The quarter also marked the completion of our portfolio transformation, which resulted in total divestiture proceeds of over $10 billion,&#8221; stated Carrier Chairman &amp; CEO <strong>David Gitlin</strong>.</p>
<p>&#8220;We successfully acquired and integrated Viessmann Climate Solutions in 2024, giving us the most comprehensive and differentiated global portfolio in our industry. We are well-positioned to deliver strong results in 2025, reinforced by our growing global commercial HVAC backlog supported by the acceleration in data centers, commitment to double-digit aftermarket growth, and leading positions across our businesses,&#8221; added Gitlin.</p>
<p><strong>2025 Outlook:</strong> Carrier projects accelerated organic growth in 2025 supported by secular tailwinds, <a href="https://www.benzinga.com/calendars/guidance">continued innovation and double-digit aftermarket growth.</a></p>
<p>The company expects mid-single-digit organic growth with reported sales between $22.5 billion and $23.0 billion versus the consensus of $23.008 billion. This is offset by a $750 million impact from the Commercial Refrigeration divestiture.</p>
<p>CARR sees adjusted EPS of $2.95 – $3.05 versus the consensus of $2.99, reflecting mid- to high-teens growth and an adjusted operating margin of 16.5%—17.0%.</p>
<p>The company forecasts free cash flow of $2.4 billion—$2.6 billion and plans to repurchase approximately $3 billion in shares.</p>
<p><strong>Price Action:</strong> CARR shares are trading lower by 3.34% at $64.02 at the last check Tuesday.</p>
<p><em>Image via Shutterstock.</em></p>


Equities

Buybacks

Movers

Carrier Global Stock Slips After Mixed Q4, CEO Bets Big On 2025 Growth

<p>Craig-Hallum  analyst Anthony Stoss   maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Hold and lowers the price target from $78 to $50.</p>


Craig-Hallum Maintains Hold on ON Semiconductor, Lowers Price Target to $50

<p>Barclays  analyst Julian Mitchell   maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Equal-Weight and raises the price target from $285 to $300.</p>


Barclays Maintains Equal-Weight on Rockwell Automation, Raises Price Target to $300

<p>B of A Securities  analyst Jason Gerberry   maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and raises the price target from $143 to $167.</p>


AXSM

B of A Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $167

Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q2 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors...

Grace Therapeutics Reports Steady Progress and Financials

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics (GRCE – Research Report). The compa...

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

Grace Therapeutics (GRCE) will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists to be held De...

Grace Therapeutics to exhibit at ASHP Conference

Grace therapeutics announces private placement financing of $30 million

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit when...

Grace Therapeutics announces results from Phase 3 STRIVE-ON trial

Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment

GRCE

Health Care

Press Releases

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

Grace Therapeutics Announces Second Fiscal Quarter 2025  Financial Results, Provides Business Update

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Financing

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

ACST

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SCYNEXIS

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Grace Therapeutics

ニュース

最新ニュース Grace Therapeutics (NASDAQ:GRCE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル